News dal mondo
29
Apr
US GDUFA IV Talks Reach Tentative Agreement; America First Application Fee Waiver Added
US FDA GDUFA Reauthorization performance goals and program enhancements Riscal years 2023-2027 - Meeting 23 giugno 2026 [Federal Register Volume 91, Issue 72 - April 15, 2026]
US FDA GDUFA Reauthorization performance goals and program enhancements Riscal years 2023-2027 - Meeting 23 giugno 2026
[Federal Register Volume 91, Issue 72 - April 15, 2026]
28
Sun Pharma compra Organon
Sun Pharmaceutical Industries ha firmato un accordo definitivo per acquisire Organon &...
27
US QMM: Participants scored well on commitment to quality, lower on advanced manufacturing
Pharmaceutical companies participating in the US Food and Drug Administration (FDA) Quality Maturity...
23
Top Drugs at Risk of Supply Shortages
Nearly half of 100 vulnerable medicines have at least one key starting material sourced exclusively...
Regulatory considerations for pharmaceutical excipient selection
The article discusses the role and importance of excipients in medicines, focusing on regulatory aspects...
le ultime news
11 Mar
EU Finalizes Pharma Reform Package, Clarifies New Rules On Modular Market Protection
PFAS restriction proposal: ECHA’s Socio-Economic Analysis Committee agrees its draft opinion
Farmaci - Gemmato: In cantiere anche un ritorno nazionale alla chimica farmaceutica di base
EMA outlines methods for evaluating supply chain vulnerabilities
09 Mar
US FDA drafts guidance on best practices for responding to inspection observations
Intelligenza Artificiale e salute: le agenzie regolatorie al centro della rivoluzione farmaceutica
06 Mar
Testo unico Legislazione Farmaceutica,: assegnato alla X Commissione Senato
04 Mar
ECHA’s Risk Assessment Committee adopts its opinion on PFAS restriction proposal
<<<4 5 6>>>
